

Pneumonia - West Virginia University

The Use of **Volara** System Oscillation and Lung Expansion (OLE) Therapy to Aid a Patient With COPD and Bronchiectasis

OVERVIEW

Report of a 73 year-old female admitted for pneumonia and COPD exacerbation with complaints of thick sputum and inability to expectorate.

HISTORY

Comorbidities include COPD and Bronchiectasis, on 3L O₂ at home. Has had multiple hospital admissions in the last several months for COPD exacerbations and pneumonia, requiring bronchoscopy for mucus plugging.

FOLLOWING ADMITTANCE

Initiated on heated high-flow nasal cannula (HFNC) and started on PEP device.

PATIENT TIMELINE

Below is the progression of the patient's status over the week:

	O ₂ REQUIREMENT	PAO ₂	THERAPY/MODALITY
Day 1	40L/70%	94 mmHg	PEP device
Day 2	40L/70%		PEP device
Day 3	40L/85%	59 mmHg	PEP device
Day 4	55L/85%	61 mmHg	PEP used until 1200, when Volara System started Q4
Day 5	40L/60%	87 mmHg	Volara System Q4
Day 6	35L/45% to 4L NC		Volara System Q4 , changed to QID with transfer from ICU to floor

EVIDENCE



Intake CXR: Pre-PEP or **Volara** System use



Day 4: Post-PEP device (3.5 days of treatment), Pre-**Volara** System OLE Therapy



Day 6: Post-**Volara** System OLE Therapy (2.5 days of treatment)

For more information, please contact your local Baxter sales representative or call Baxter Customer Service at **1-800-426-4224**.

Rx Only. For safe and proper use of product mentioned herein, please refer to the Instructions for Use or Operator Manual.

Baxter.com

Baxter International Inc.
One Baxter Parkway / Deerfield, Illinois 60015

Hill-Rom reserves the right to make changes without notice in design, specifications and models. The only warranty Hill-Rom makes is the express written warranty extended on the sale or rental of its products.

Baxter and Volara are trademarks of Baxter International Inc. or its subsidiaries.

US-FLC188-240002 (v2.0) 09/2024